Shares of EDGE MEDICAL-B (02675) experienced a significant rally during the late trading session, climbing nearly 20%. At the time of writing, the stock was up 14.27% to HK$39.88, with a trading volume of HK$53.698 million.
The surge follows recent news from a major medical conference in Shanghai. The company showcased its self-developed multi-port endoscopic surgical robot system at the event. At the exhibition, experts and scholars from fields including pancreatic surgery, hepatobiliary surgery, and digestive surgery engaged in in-depth discussions with the company's team. Topics covered system operation, adaptation for complex procedures, expansion of clinical applications, and remote surgical collaboration.
Key Commercial Progress
Public information indicates that EDGE MEDICAL's multi-port endoscopic surgical robot has now received regulatory approval for market access in 55 countries and regions. This includes Europe, Asia-Pacific, the Middle East, Africa, and Central and South America. Furthermore, its single-port robot and a combined multi-port/single-port product have secured approvals in 35 countries and regions.
Sales Performance
The company's commercialization efforts are showing tangible results. By the end of last year, EDGE MEDICAL had signed agreements for the sale of 119 units of its core products globally. Notably, 92 of these units were contracted for sale within the last year alone, highlighting accelerating commercial traction.
Comments